AMN Life is a 100% EOU pharma company that has developed a wide range of innovative formulations in various dosage forms. These formulations cater to the therapeutic needs for allergic disorder, bacterial and fungal infections, malaria, erectile dysfunction, Diabetes and Cardio-vascular diseases to name a few. Amihepa, Renoket, Avam, S-Valapro, Suncetin, Asita and Amcort are few of the AMN Life brands that command a leadership position in the covered markets. Present in 25 countries, AMN Life’s success holds dominant position in south East Asian market, poised to grow its presence to almost 150 countries across the globe.

Under the leadership of Mr. Ashish, the exports of AMN Life showed a year-on-year growth of more than 100% in financial year 2007 and bagged the Indian Exporters’ Excellence Award. Continuing its growth trajectory over the years, the Company bagged SME business excellence Awards and leading SMEs of India 2016 in the Pharmaceuticals sector.

Mr. Ashish’s innovative entrepreneurial skill resulted in Acquisitions of ASA LIFE, Singapore in year 2018 and many more acquisitions are planned along with setting up offices worldwide. In the immediate future, AMN Life is poised to grow to achieve a dominating presence in the European union with provision for In-licencing and out – licencing opportunities. Today the Group boasts of more than 10 Companies India and Overseas and registered the sales turnover of more than Rs. 250 Crore across the group companies.

The Entrepreneur strives to drive operational excellence in every department within his business. It is not an easy concept to quantify, and very difficult to explain in simple practical terms to operators of different departments, however, he managed to overcome these challenges. Besides, he always guides the team to justify and use cost-efficient technologies, to bring out top quality products that are economical and reliable.

Mr. Ashish’s innovation strategy involves streamlining an increasingly complex manufacturing system. This type of next-generation innovation wades through the growing sea of new ideas and emerges with the strategies that deliver a clear and focused value in the form of targeted Acquisitions and partnerships, personalised treatments, efficient outsourcing partners and properly integrated innovative technologies, but perhaps this statement has wider implications for today’s pharmaceutical industry.

He believes that, the practice of cranking out rapid-fire innovation in the form of new molecules with the hopes of finding the next blockbuster is being replaced by targeted innovation strategies that demonstrate actual patient value and reach that can be duplicated across an enterprise.

Under his leadership, AMN Life is currently eying the EU certification along with highly professional team of 200 plus professionals and available to consider new alliance opportunities in the uncontested zones of in In-licensing, co-promotion, revenue sharing and carved partnership opportunities.

Mr. Ashish has also undertaken challenging green initiatives, which is reflected throughout AMN Life’s Supply Chain. The issue of Pharmaceuticals in the Environment (what some call PIE) has garnered plenty of media attention, mostly negative in the past several years. Most of the concern with drugs in the environment revolves around consumers who either excrete un-metabolised active ingredients or dispose of unused medications into sewage systems. Under his leadership, AMN Life is able to ensure complete deactivation of waste residues by using alkaline solution before it is being sent to centralised insemination.

Mr. Ashish hopes to provide

Access to life,
Access to healthy life
for everyone.